With pharma and life sciences deal values surpassing $65 billion in Q1, marking the strongest quarter in the industry since 2020, analysts from PwC have declared that the “biopharma ecosystem is back ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results